Publications by authors named "A Gailhajanet"
Purpose The aim of this study was to compare Basque and Catalan bilinguals' performance on the letter verbal fluency test and determine whether significant differences are present depending on the letters used and the language of administration. Method The sample consisted of 87 Spanish monolinguals, 139 Basque bilinguals, and 130 Catalan bilinguals from Spain. Participants completed the letter verbal fluency test using the letters F, A, S, M, R, P, and E.
View Article and Find Full Text PDFBackground: Peripheral biomarkers that identify individuals at risk of developing Alzheimer's disease (AD) or predicting high amyloid beta (Aβ) brain burden would be highly valuable. To facilitate clinical trials of disease-modifying therapies, plasma concentrations of Aβ species are good candidates for peripheral AD biomarkers, but studies to date have generated conflicting results.
Methods: The Fundació ACE Healthy Brain Initiative (FACEHBI) study uses a convenience sample of 200 individuals diagnosed with subjective cognitive decline (SCD) at the Fundació ACE (Barcelona, Spain) who underwent amyloid florbetaben(F) (FBB) positron emission tomography (PET) brain imaging.
Article Synopsis
- The Face-Name Associative Memory Exam (FNAME) is designed to identify memory issues in people with early signs of Alzheimer's disease (AD).
- Research found that worse performance on the Spanish version (S-FNAME) correlates with higher amyloid beta (Aβ) levels, indicating potential memory decline.
- In a study of 200 individuals with subjective cognitive decline, those who performed poorly on the face-name memory task showed significant links between their performance and Aβ levels, particularly in the Posterior Cingulate Cortex, suggesting its usefulness in early detection of AD.
Background: Long-term longitudinal studies with multimodal biomarkers are needed to delve into the knowledge of preclinical AD. Subjective cognitive decline has been proposed as a risk factor for the development of cognitive impairment. Thus, including individuals with SCD in observational studies may be a cost-effective strategy to increase the prevalence of preclinical AD in the sample.
View Article and Find Full Text PDFExploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results.
Alzheimers Dement
May 2018
Article Synopsis
- Subjective cognitive decline (SCD) might indicate early signs of Alzheimer's disease (AD), but the genetic and biomarker characteristics of SCD individuals are still not well understood.
- A study evaluated the influence of the APOE ε4 gene on SCD risk using data from the FACEHBI cohort and Spanish controls, revealing that SCD individuals had higher frequencies of the APOE ε4 allele than non-SCD individuals.
- Results showed that the amount of APOE ε4 was linked to higher cerebral amyloid levels, indicating that while APOE dosage accounts for part of the variability in amyloid levels, other genetic or epigenetic factors are likely also at play in SCD.